View
4
Download
0
Category
Preview:
Citation preview
Novedades terapéuticas en Novedades terapéuticas en neoplasias neoplasias mieloproliferativasmieloproliferativasneoplasias neoplasias mieloproliferativasmieloproliferativas
Juan Carlos Hernández Boluda
Hospital Clínico Universitario de Valencia
2ª Reunión Científica GEMFIN
Madrid, Abril 2017
Tratamiento de la TE y PV
• Final results from the phase 3 trial ARETA comparing a novel extended-release anagrelide formulation to placebo in ET pts with defined risk status(abstr 0476).
– H. Gisslinger, University of Vienna, Austria.
• Final results from PROUD-PV a randomized controlled phase 3 trial• Final results from PROUD-PV a randomized controlled phase 3 trialcomparing Ropeginterferon alfa-2b to hydroxyurea in PV patients (abstr0475).
– H. Gisslinger, University of Vienna, Austria.
• Interim analysis of the MPD-RC 112 global phase III trial of front-linepegylated interferon vs. Hydroxyurea in high risk PV and ET (abstr 0479).
– J.O. Mascarenhas, Icahn School of Medicine at Mount Sinai, NY, US.
Development goals are to achieve:– lower peak plasma
concentration of anagrelide– reduction of the frequency
and intensity of peak-concentration related adverse events (AEs)
– easier dosing scheme (once daily vs. 2-3 times daily)
Anagrelide extended release
H Gisslinger, ASH 2016
daily vs. 2-3 times daily)– improved patient compliance
Extended release tablet containing 2mg anagrelide
Strength based on 60-70% bio-availability compared to commercial immediate release formulations
H Gisslinger, ASH 2016
Promotor: AOP Orphan Pharmaceuticals AG
H Gisslinger, ASH 2016
H Gisslinger, ASH 2016
H Gisslinger, ASH 2016
H Gisslinger, ASH 2016
H Gisslinger, ASH 2016
Promotor: AOP Orphan Pharmaceuticals AG
AOP2014 (n=127) HU (n=127)
Caucasian 100% 100%
WHO2008 PV *) 100% 100%
Female 53.5% 52.8%
Age (median, range) 60 (30-85) 60 (21-81)
Disease duration (median, range) 1.9 month (0-146) 3.6 month (0-126)
AOP2014 (n=127) HU (n=127)
Caucasian 100% 100%
WHO2008 PV *) 100% 100%
Female 53.5% 52.8%
Age (median, range) 60 (30-85) 60 (21-81)
Disease duration (median, range) 1.9 month (0-146) 3.6 month (0-126)
Patient baseline demographics
Disease duration (median, range) 1.9 month (0-146) 3.6 month (0-126)
HU pretreated 47 (37%) 47 (37%)
Hematocrit (mean, SD) 49.5% (±5.4) 49.8% (±5.5)
Spleen length (median, range) 13.1 cm (7.0-25.0) 13.0 cm (7.5-24.5)
Spleen normal/slightly enlarged **) 90.6% 88.2%
Spleen length >17cm/>22cm 9.4%/2.4% 11.8%/3.9%
Mean JAK2V617F burden 42% 43%
Disease duration (median, range) 1.9 month (0-146) 3.6 month (0-126)
HU pretreated 47 (37%) 47 (37%)
Hematocrit (mean, SD) 49.5% (±5.4) 49.8% (±5.5)
Spleen length (median, range) 13.1 cm (7.0-25.0) 13.0 cm (7.5-24.5)
Spleen normal/slightly enlarged **) 90.6% 88.2%
Spleen length >17cm/>22cm 9.4%/2.4% 11.8%/3.9%
Mean JAK2V617F burden 42% 43%
*) confirmed by bone marrow biopsy**) slightly enlarged >12/13cm (f/m) – 17cm
*) confirmed by bone marrow biopsy**) slightly enlarged >12/13cm (f/m) – 17cm
H Gisslinger, ASH 2016
H Gisslinger, ASH 2016
H Gisslinger, ASH 2016
H Gisslinger, ASH 2016
H Gisslinger, ASH 2016
JO Mascarenhas, ASH 2016
PEGASYS (Roche): IFN-pegilado α-2a
Baseline characteristics of first 75 patients on the MPD -RC 112 trial
HU (n=39) PEG (n=36) Total (n=75) P
Value*
Age, years median (range) 66 (28-85) 56 (20-71) 61 (20-85) <0.001
Gender, Female 19 (49%) 16 (44%) 35 (47%) 0.71
MPN subtype, ET/PV 16 (41%) /23 (59%) 15 (42%)/21 (58%) 31 (41%) /44 (59%) 0.95
JAK2V617F 36 (92%) 32 (89%) 68 (91%) 0.51
ECOG PS, 0 34 (87%) 29 (81%) 63 (84%) 0.44
Age >60 years 27 (69%) 15 (42%) 42 (56%) 0.02
History of venous thrombosis 6 (15%) 5 (14%) 11 (15%) 0.86
HU (n=39) PEG (n=36) Total (n=75) P
Value*
Age, years median (range) 66 (28-85) 56 (20-71) 61 (20-85) <0.001
Gender, Female 19 (49%) 16 (44%) 35 (47%) 0.71
MPN subtype, ET/PV 16 (41%) /23 (59%) 15 (42%)/21 (58%) 31 (41%) /44 (59%) 0.95
JAK2V617F 36 (92%) 32 (89%) 68 (91%) 0.51
ECOG PS, 0 34 (87%) 29 (81%) 63 (84%) 0.44
Age >60 years 27 (69%) 15 (42%) 42 (56%) 0.02
History of venous thrombosis 6 (15%) 5 (14%) 11 (15%) 0.86
* Based on t-test for continuous variables and z-test for binary variables.- -
History of venous thrombosis 6 (15%) 5 (14%) 11 (15%) 0.86
History of arterial thrombosis 4 (10%) 9 (25%) 13 (17%) 0.09
Cardiovascular risk factors 25 (64%) 16 (44%) 41 (55%) 0.09
Palpable spleen 10 (26%) 7 (19%) 17 (23%) 0.52
Spleen length by palpation (cm
below left costal margin)
1.5 (0-10) 1.0 (0-10) 1.3 (0-10) 0.52
Spleen length by ultrasound (cm) 12.4 (0-18) 13.0 (0-20.2) 12.6 (0-20.2) 0.90
Leukocytes (x 109/L) 10.3 (4.8-20.0) 8.1 (4.0-23.4) 9.3 (4.0-23.4) 0.43
Hemoglobin (g/dL) 14.1 (12.1-22.4) 14.4 (11.3-16.6) 14.4 (11.3-16.6) 0.17
Hematocrit (%) 45.7 (36.2-70.2) 43.9 (33.5-60.7) 45.0 (33.5 -70.2) 0.33
Platelets (x 109/L) 615 (142-1444) 538 (112-1382) 592 (112-1444) 0.24
History of venous thrombosis 6 (15%) 5 (14%) 11 (15%) 0.86
History of arterial thrombosis 4 (10%) 9 (25%) 13 (17%) 0.09
Cardiovascular risk factors 25 (64%) 16 (44%) 41 (55%) 0.09
Palpable spleen 10 (26%) 7 (19%) 17 (23%) 0.52
Spleen length by palpation (cm
below left costal margin)
1.5 (0-10) 1.0 (0-10) 1.3 (0-10) 0.52
Spleen length by ultrasound (cm) 12.4 (0-18) 13.0 (0-20.2) 12.6 (0-20.2) 0.90
Leukocytes (x 109/L) 10.3 (4.8-20.0) 8.1 (4.0-23.4) 9.3 (4.0-23.4) 0.43
Hemoglobin (g/dL) 14.1 (12.1-22.4) 14.4 (11.3-16.6) 14.4 (11.3-16.6) 0.17
Hematocrit (%) 45.7 (36.2-70.2) 43.9 (33.5-60.7) 45.0 (33.5 -70.2) 0.33
Platelets (x 109/L) 615 (142-1444) 538 (112-1382) 592 (112-1444) 0.24
JO Mascarenhas, ASH 2016
JO Mascarenhas, ASH 2016
Complete Histopathologic Bone Marrow Response at 12 mo by Blinded Central
Review
HU PEG
ET+PV 8/22 2/24
Histopathology Criteria� Normalized BM
cellularity � < grade 2 reticulin
fibrosis
ET 5/10 2/10
PV 3/12 0/14
� ET: Disappearance of
megakaryocyte
hyperplasia, and
abnormal
megakaryocyte
histotopography
� PV: Disappearance of
trilineage hyperplasia
JO Mascarenhas, ASH 2016
Tratamiento de la MF
• Results of the PERSIST-2 phase 3 study of pacritinib vs. Best availabletherapy, including ruxolitinib, in pts with MF and platelet counts<100,000/µl (LBA-5).
– J.O. Mascarenhas, Icahn School of Medicine at Mount Sinai, NY, US.
• Momelotinib therapy in myelofibrosis: 6-years follow-up data on safety,efficacy and the impact of mutations on overall and relapse-free survivalefficacy and the impact of mutations on overall and relapse-free survival(abstr 1123).
– A. Tefferi, Mayo Clinic, Rochester, US.
• Ensayos fase 3 de momelotinib en mielofibrosis (Simplify 1 & 2)– Avance de resultados por Gilead.
Background
• MF is a life-threatening hematologic malignancy characterized by splenomegaly and debilitating constitutional symptoms1-3
– ~1/4 of MF pts present with thrombocytopenia;4 platelets <50,000/µL associated with reduced QoL,1 more severe symptom burden, and shorter overall survival5
• Approved JAK1/2 inhibitor RUX reduces splenomegaly and symptoms, but is associated with dose-limiting cytopenias and not indicated for pts with platelets <50,000/µL6,7with platelets <50,000/µL6,7
• PAC: oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, & CSF1R8
• PERSIST-1 trial : sustained spleen volume reduction (SVR) and symptom control with PAC vs BAT (excluding JAK2 inhibitors) in pts with MF regardless of baseline platelet count 9
• PAC placed on full clinical hold by the US FDA (2/8/2016) due to concerns over interim survival results, bleeding, and cardiovascular events
JO Mascarenhas, ASH 2016
PERSIST-2 Phase 3 Study Design
JO Mascarenhas, ASH 2016
Patient Demographics (Cont’d)(ITT Efficacy Population)
JO Mascarenhas, ASH 2016
Patient Disposition
JO Mascarenhas, ASH 2016
Study Treatment
JO Mascarenhas, ASH 2016
Efficacy Summary
JO Mascarenhas, ASH 2016
Efficacy: Analysis by Arm
15% 22% 3%
JO Mascarenhas, ASH 2016
14%32%17%
Overall Survival (Censored at Date of Clinical Hold)
JO Mascarenhas, ASH 2016
Serious TEAEs
JO Mascarenhas, ASH 2016
Momelotinib in MF: 6 -years follow -upPhase 1-2 trial (n=100)
• DIPSS+: High/Int-2 99%
• Median follow-up: 3.2 yrs
• Discontinuation: 88 pts
• Peripheral neurotoxicity G1/2: 47%
A Tefferi, ASH 2016
• Peripheral neurotoxicity G1/2: 47%
• Anemia response: 44%
• Spleen response: 43%
• SRV at 5 yr: 32%
Ensayos fase 3 de momelotinib en mielofibrosis
JAK inhibitor naïve
• Randomized, Double Blind
• Primary endpoint: Spleen Response by MRI at week 24
Ruxolitinib + placebo
N = 420 1:1
randomization
Momelotinib + placebo
Previous JAK inhibitor exposure
• Randomized, Open Label
• Required ruxolitinib dose adjustment to < 20mg BID and concurrent hematologic toxicity
• Primary endpoint: Spleen Response by MRI at week 24
N = 150 2:1
randomization
MomelotinibN = 100
Best Available Therapy (ruxolitinib and no treatment allowed)
N = 50
Day 1 Week 24 Year 5
Year 5Day 1 Week 24
Ensayos Simplify: datos no publicados
SIMPLIFY-1
• Objetivo 1º: resp. esplénica sem 24:– 26.5% Momelotinib– 29% Ruxolitinib� No inferioridad (p=0.011)
SIMPLIFY-2
• Objetivo 1º: resp. esplénica sem 24:– 6.7% Momelotinib– 5.8% BAT (88% ruxolitinib)� Superioridad (p=0.90)� No inferioridad (p=0.011)
• Objetivo 2º: resp. control síntomas:– Ruxolitinib mejor
� Superioridad (p=0.90)
Inhibidores de cinasas JAK en MF
Ruxolitinib (Jakavi ®) Novartis JAK1, JAK2 Aprobado
Momelotinib (CYT387) Gilead JAK1, JAK2 III (retirado)
Pacritinib (SB1518) CTI-Bio/Baxalta JAK2, FLT3 III
NS-018 NS Pharma JAK2 I/II
Agente Compañía Diana Fase
NS-018 NS Pharma JAK2 I/II
Itacitinib (INCB039110) Incyte JAK1 II
Fedratinib (SAR302503) Sanofi JAK2, FLT3 III (retirado)
Gandotinib (LY2784544) Lilly JAK2 I (retirado)
Lestaurtinib (CEP701) Cephalon JAK2, FLT3 II (retirado)
AZD1480 AstraZeneca JAK2, JAK1 I (retirado)
XL019 Exelixis JAK2 I (retirado)
Fármacos frente a otras dianas
PEG-IFN α-2a (Pegasys ) Roche Inmunomodulador II
Nivolumab BMS PD1 II
Panobinostat (Faridak ) Novartis Histona deacetilasa II
Azacitidina (Vidaza®) Pharmion Metiltransferasa II
Sonidegib (LDE225) Novartis Smoothened Ib/II
Agente Compañía Diana Fase
Saridegib (IPI926) Infinity Hedgeh og I
Imetelstat Geron/Janssen Telomerasa II
Buparlisib (BKM120) Novartis PI3K I
Everolimus (Afinitor®) Novartis mTOR I/I
Luminespib (AUY922) Novartis HSP90 II
Simtuzumab (GS6624) Gilead LOXL2 II
PRM151 Promedior Agonista PTX2 II
Estudios de combinación de ruxolitinib con otros fármacos en mielofibrosis
Ruxo + danazol (fase II)
Ruxo + pomalidomida (fase I-II)
Ruxo + lenalidomida (fase II)
Ruxo + panobinostat (fase I-II)
Ruxo + azacitidina (fase II)
Ruxo + buparlisib (fase I)
Ruxo + sonidegib (fase Ib-II)
Ruxo + interferón α2 (fase II)
Ruxo + nilotinib + prednisona (fase Ib-II)
www.ClinicalTrials.gov
Recommended